Global
About Us
Company Profile
Milestones
Core Team
Science and Technology
Research Field
Technology Platform
Product Pipeline
Manufacturing Plants
Intellectual Property Rights
Investor Relations
Company Information
Financial Reports
Announcements and Circulars
Corporate Governance
News Centre
Company News
Media Coverage
Join Us
Corporate Culture
Business Outlook
Benefits
Job Opportunities
Contact us
Shanghai
Beijing
Overseas
NEWS CENTRE
News Centre
Company News
Media Coverage
Year
2024
2023
2022
2021
2020
2019
2018
Month
01
02
03
04
05
06
07
08
09
10
11
12
2024-05-24 12:34
VOLUNTARY ANNOUNCEMENT THREE C
A. INTRODUCTION This announcement is made by Lepu Biopharma Co., Ltd. (the “Company”) on a voluntarybasis. The board of directors of the Company (the “Board...
More
2024-03-11 18:29
FAST TRACK DESIGNATION GRANTED...
March 11, 2024,Lepu Biopharma Co., Ltd. (the “Company”) announce that, our drug candidate MRG004A, a novel tissue factor-targeted site-specifically conjugated antibody drug conjugate, has ...
More
2023-12-29 10:37
COMPLETION OF PATIENT ENROLLME...
29 December, 2023, Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) is pleased to announce that, our drug candidate MRG003, an antibody drug conjugate (“ADC”) drug candidate targeting epide...
More
2023-12-14 11:35
ORPHAN-DRUG DESIGNATION GRANTE...
14 December, 2023, Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) is pleased to announce that our drug candidate MRG004A, a novel tissue factor-targeted site-specifically conjugated antibody drug con...
More
2023-10-23
ESMO Conference | MRG003 HNSCC Clinical Data Release
2023-02-23
Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901
2022-09-30
Pucotenlimab obtains approval for marketing with new achievements | Professor Guo Jun: The approval of pucotenlimab for
2022-09-30
Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication and brings a new treatment optio
2022-07-22
Anti-PD-1 monoclonal antibody Puyouheng (pucotenlimab injection) developed by LEPU BIOPHARMA was approved for marketing
2021-04-20
Lepu Biopharma Completed Series C Financing
<
1
2
3
>
Home Page
Company Profile
Strategic Investors
Technical Strength
News Centre
About Us
Company Profile
Milestones
Core Team
Science and Technology
Research Field
Technology Platform
Product Pipeline
Manufacturing Plants
Intellectual Property Rights
Investor Relations
Company Information
Financial Reports
Announcements and Circulars
Corporate Governance
News Centre
Company News
Media Coverage
Join Us
Corporate Culture
Business Outlook
Benefits
Job Opportunities
Contact us
Copyright 2021 By Lepu Biopharma CO.,Ltd.
京公网安备11011702000459号
京ICP备20018649号-1
Home Page
About Us
Science and Technology
Strategic Investors
News Centre
Join Us
Contact Us